-GAD Diagnosis Increases Healthcare Costs and Decreases Work Productivity and Health-Related Quality of Life-

-People with Undiagnosed GAD Incur Even Higher Total Healthcare Costs than those Diagnosed with GAD-

-Comprehensive Analyses of GAD Disease Burden in the US Conducted by MindMed; Company is Investigating New Treatments for GAD and Other Brain Health Disorders-

Researchers from Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented new studies highlighting the significant impact of GAD in the US at ISPOR 2024, the leading global conference for health economics and outcomes research (HEOR) being held this week in Atlanta.

This press release features multimedia. View the full release here:

Figure 1. Work Productivity: Absenteeism, presenteeism, overall work productivity loss and activity impairment: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls are marked with asterisks. Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay. Absenteeism was not calculated for those who worked 0 hours and missed 0 hours in the last 7 days, and presenteeism was only asked among those who worked >0 hours in the last 7 days. (Abbreviations: GAD: generalized anxiety disorder.) (Graphic: Business Wire)

Three studies examined the impact of GAD on healthcare utilization and costs, workplace productivity, and healthcare quality of life (HC QOL). All three studies demonstrated that the economic and societal impact of GAD is substantial, gets worse when anxiety symptoms are more severe, and is more significant when GAD is present but undiagnosed.

"These studies clearly demonstrate that the burden of GAD on the US healthcare system, employers, and people living with GAD is enormous. We continue to discover evidence that the impact of GAD has been underappreciated and that people living with this disorder are underserved," said Daniel R. Karlin, MD, MA, Chief Medical Officer of MindMed and senior author of these studies. "We undertook these studies as part of our commitment to highlight the scale of the anxiety crisis and our mission to address this burden. The results of these in-depth analyses speak for themselves."

The studies were conducted using data from the 2022 National Health and Wellness Survey (NHWS; N=75,261). The NHWS is an annual internet-based survey; all data are self-reported. Recruitment is designed to represent the general US adult population in terms of age, race, ethnicity and gender distribution. Participants were requested to use the clinically validated GAD-7 screening tool as recently recommended by the US Preventive Services Task Force (USPSTF).

Three studies were presented at ISPOR 24:

- Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States
- Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States
- Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States